Using sonidegib before surgery to treat basal cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of sonidegib, a daily oral medication, as a neoadjuvant treatment for patients with resectable basal cell carcinoma (BCC) located in cosmetically sensitive areas. The goal is to reduce tumor size over a 12-week period, potentially allowing for less invasive surgery or even avoiding surgery altogether. The study will utilize optical coherence technology (OCT) to assess tumor response and guide treatment decisions. By combining drug treatment with advanced imaging techniques, the study aims to improve surgical outcomes and reduce the risk of recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years of age.
* Written informed consent.
* Histologically confirmed, resectable, invasive basal cell carcinoma.
* Site and size of BCC considered to be in a cosmetically challenging position for surgery.
* Patient has expressed concerns of the cosmetic outcome of surgery.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
* Ability to swallow and retain oral medication.
* Anticipated life expectancy of \> 12 months.
* Adequate organ function as demonstrated by blood tests.
* Willing to abstain from blood donations for 20 months from the last dose of sonidegib.
* Men with female partner of childbearing potential to use effective contraception from 14 days prior to study treatment until 6 months after the last dose.
* Female patients with active contraception or no menstrual cycle for \>12 months

Exclusion Criteria:

* Inoperable basal cell carcinoma tumours.
* A concurrent cancer diagnosis requiring any systemic anti-cancer therapy.
* Serious or unstable pre-existing medical conditions or other conditions or laboratory abnormalities that could interfere with the patient's safety, consent, or compliance.
* History of malabsorption or other conditions that would interfere with the absorption of sonidegib.
* Known psychiatric or substance abuse disorders that would interfere with cooperation and compliance with the requirements of the trial.
* Prior treatment with hedgehog pathway inhibitors.
* Concomitant medications that may result in increased or decreased bioavailability of sonidegib.
* Patients with neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, rhabdomyolysis, amyotrophic lateral sclerosis and spinal muscular atrophy) due to an increased risk of muscle toxicity with sonidegib.
* Male patients expecting to father children or donate sperm during the 12 weeks of sonidegib treatment and for a further 6 months from the end of treatment.
* Pregnant or breastfeeding women

Where it's running

• Melanoma Institute Australia
  North Sydney, New South Wales, Australia Recruiting

Study contacts

• Study coordinator: Pascale Guitera, MD PhD
• Email: pascale.guitera@melanoma.org.au
• Phone: +61299117296

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Raman Spectroscopy to assess skin cancer tumors

  This study is testing a new imaging technique to see if it can help doctors better understand the size and spread of skin cancer tumors in patients with basal cell and squamous cell carcinoma.

  Recruiting Stony Brook University · Stony Brook, New York · NCT06384924

• Evaluating oral hedgehog inhibitors for treating basal cell carcinoma in the Netherlands

  This study is testing if two oral medications, vismodegib and sonidegib, can help people with advanced basal cell carcinoma or Gorlin syndrome feel better and improve their condition.

  Recruiting at 7 sites Maastricht University Medical Center · Nijmegen, Gelderland and 7 other locations · NCT05463757

• Mobile sun protection support to help young adults stay safe in the sun

  This project tests a mobile health program to see if reminders, education, planning tools, and real-time sun exposure information can help young adults protect their skin from excessive sun exposure.

  Recruiting University of Utah · Salt Lake City, Utah · NCT07830394

• AI-based risk and subtype prediction for basal cell carcinoma using dermoscopic images

  A retrospective study tests an artificial intelligence model to classify basal cell carcinoma as low- or high-risk and to predict histopathological subtypes from archived dermoscopic images.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Istanbul · NCT07677124

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Psycho-physiological profiling of people with low versus high heat resilience

  This project will test whether controlled heat and UV exposures plus physiological and psychological measurements can identify healthy adults who are more or less resilient to heat.

  Recruiting at 2 sites University of Thessaly · Copenhagen and 1 other locations · NCT07510061

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.